Quick jump to page content
  • Main Navigation
  • Main Content
  • Sidebar
  • Register
  • Login
##common.pageHeaderLogo.altText##
  • Home
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Current
  • Archives
  • Submission

Search

Advanced filters

Search Results

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Andrew Blauvelt, Lars Iversen, Sandy McBride, Melinda Gooderham, Petra Staubach, Paul Yamauchi, Fabienne Staelens, Veerle Vanoorden, Katy White, Paolo Gisondi

Page s53

Poster PDF

Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials

Andrew Blauvelt, George Han, Steve Tyring, Jennifer Soung, Tae Oh, Leah Davis, Veerle Vanoorden, Mark Lebwohl

Page s55

Poster PDF

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich

Page s15

Poster PDF

Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

B Strober, JG Krueger, N Magnolo, R Vender, DP Toth, D Thaci, M Wang, C Cioffi, C Madden, RB Warren

Page s16

Poster PDF

Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial

K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola

Page s17

Poster PDF
1 - 5 of 5 items

 

 

 

 

180x77

Make a Submission

SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to providing an enhanced route to disseminate new dermatologic knowledge on all aspects of cutaneous disease. The Journal is Open Access. ISSN: 2574-1624

Important Links

  • About the Journal
  • Editorial Team
  • Submissions
  • Contact

Contact

  • Email: jofskin@gmail.com
  • Website: www.jofskin.org
  • Mailing Address: PO Box 569 Millwood NY 10546
OJS Hosting, Support, and Customization by: OpenJournalSystems.com

Modal Header